Optimizing duration of pharmacotherapy in patients with irritable bowel syndrome: an Indian perspective
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242973Keywords:
IBS, Gut-brain dysregulation, Anxiety, AntispasmodicsAbstract
Irritable bowel syndrome (IBS) is the most common gut-brain disorder with a rising prevalence globally, including in India. IBS places a major financial and health burden on patients, making a proper diagnosis and course of treatment crucial for enhancing quality of life. The frequent occurrence of anxiety and depression in patients with IBS requires the treatment of both gastrointestinal and psychological symptoms of the condition with antispasmodics and anxiolytics. This review discusses the epidemiological, diagnostic, and pathophysiological features of IBS and the numerous treatment regimens that are utilized, as well as the perspectives of specialists in the area addressing the difficulties and ideal management techniques. The role of combination treatments along with emphasis on associated psychological and psychiatric comorbidities in Indian patients has been evaluated. The experts reviewed the ideal duration of antispasmodic medication and various guideline recommendations on length of treatment to avoid recurrence while keeping in mind the chronic and recurring character of IBS. An appropriate diagnostic strategy and effective treatment protocol and duration can help in the long-term management of IBS.
References
Longstreth GF, Thompson WG, Chey WD, Houghton HA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017;6(11):99.
Nelkowska DD. Treating irritable bowel syndrome through an interdisciplinary approach. Ann Gastroenterol. 2020;33(1):1-8.
Hahn B, Watson M, Yan S, Gunput D, Heuijerjans J. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci. 1998;43(12):2715-8.
Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113(10):1540-9.
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-86.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-4.
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99-114.
Nagaonkar SN, Singh VS, Kangule DT, Sadhanala S. A study of prevalence and determinants of irritable bowel syndrome in an urban slum community in Mumbai. J Datta Meghe Inst Med Sci Univ. 2018;13(2):87-90.
Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: a review. World J Gastroenterol. 2017;23(37):6788-801.
Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABIa-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. Nutrients. 2020;12(2):363.
El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2015;21(25):621-7636.
Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1(2):133-46.
Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-60.
Jeong H, Lee HR, Yoo BC, Park SM. Manning criteria in irritable bowel syndrome: its diagnostic significance. Korean J Int Med. 1993;8(1):34-9.
Schmulson MJ, Drossman DA. What’s new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63.
Gwee KA, Gonlachanvit S, Ghoshal UC, Chua ASB, Miwa H, Wu J, et al. Second Asian consensus on irritable bowel syndrome. J Neurogastroenterol Motil. 2019;25(3):343-62.
Ghoshal UC, Sachdeva S, Pratap N, Karyampudi A, Mustafa U, Abraham P, et al. Indian consensus statement on irritable bowel syndrome in adults: a guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology. Indian J Gastroenterol. 2023;42(2):249-73.
Tang HY, Jiang AJ, Wang XY, Wang H, Guan YY, Li F, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187.
Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47(11):1177-85.
Stanculete MF. Psychiatric comorbidities in irritable bowel syndrome. In: Irritable bowel syndrome-novel concepts for research and treatment. IntechOpen. 2016.
Fadgyas-Stanculete M, Buga A-M, Popa-Wagner A, Dumitrascu DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014;2:4.
Kabra N, Nadkarni A. Prevalence of depression and anxiety in irritable bowel syndrome: a clinic based study from India. Indian J Psychiatry. 2013;55(1):77-80.
Sharma S, Pinto C, Masand PS, Virk S, Kaplan D, Nihalani N, et al. Relationship of irritable bowel syndrome (IBS) and major depression in Mumbai, India. Int J Psych Clin Prac. 2003;7(2):127-30.
Hu Z, Li M, Yao L, Wang Y, Wang E, Yuan J, et al. The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis. BMC Gastroenterol. 2021;21(1);23.
Balon R, Sonino N, Rafanelli C. Benzodiazepines’ role in managing gastrointestinal disorders. Psychother Psychosom. 2021;90(2):81-4.
Linedale EC, Andrews JM. Diagnosis and management of irritable bowel syndrome: a guide for the generalist. Med J Aust. 2017;207(7):309-15.
Farmer AD, Wood E, Ruffle JK. An approach to the care of patients with irritable bowel syndrome. CMAJ. 2020;192(11):E275-82.
Ghoshal UC, Rahman MM, Pratap N, Misra A, Sarker SA, Hasan M, et al. Comparisons of the Rome III and Rome IV criteria for diagnosis of irritable bowel syndrome in Indian and Bangladeshi communities and internal shifts in the diagnostic categories of bowel disorders of gut-brain interactions. Neurogastroenterol Motil. 2023;35(6):e14579.
Ferreira AI, Garrido M, Castro-Pocas F. Irritable bowel syndrome: news from an old disorder. GE Port J Gastroenterol. 2020;27(4):255-68.
Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:016014.
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770-98.
Cashman MD, Martin DK, Dhillon S, Puli SR. Irritable bowel syndrome: a clinical review. Curr Rheumatol Rev. 2016;12(1):13-26.
Annahazi A, Roka R, Rosztoczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43.
Peyton L, Greene J. Irritable bowel syndrome: current and emerging treatment options. PT. 2014;39(8):567-78.
Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9(1):7-17.
Song KH, Jung HK, Kim HJ, Koo HS, Kwan YH, Shin HD, et al. Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition. J Neurogastroenterol Motil. 2018;24(2):197-215.
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15(13):1548-53.
Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis. 2009;41(12):854-62.
McHardy G, Sekinger D, Balart L, Cradic HE. Chlordiazepoxide--clidinium bromide in gastrointestinal disorders: controlled clinical studies. Gastroenterology. 1968;54:508-13.
Hock CW. Clinical trial of Librax in gastrointestinal disorders. J New Drugs. 1961;1:90-95.
Puasripun S, Thinrungroj N, Pinyopornpanish K, Kijdamrongthum P, Leerapun A, Chitapanarux T, et al. Efficacy and safety of-clidinium/chlordiazepoxide as an add-on therapy in functional dyspepsia: a randomized, controlled trial. J Neurogastroenterol Motil. 2020;26(2):259-66.
Lacy BE, Weiser K, Lee RD. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2(4):221-38.
Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96(10):2905-14.
Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14(12):1331-8.
Irritable bowel syndrome in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE), (NICE Clinical Guidelines, No. 61. 2017.
Irritable bowel syndrome-clinical evaluation of products for treatment. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irritable-bowel-syndrome-clinical-evaluation-products-treatment. Accessed on 5 June 2024.
Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf. Accessed on 5 June 2024.
